A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

Conditions: Melanoma Interventions: Drug: fianlimab; Drug: cemiplimab; Drug: relatlimab+nivolumab Sponsors: Regeneron Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials